Millennium: Genes Are Not Enough
Executive Summary
To push forward their gene-based discovery programs, drug firms need qualified targets, not simply genetic information. Millennium is trying to provide these targets—and its signing higher-value deals as a result.You may also be interested in...
Takeda/ Millennium: The Price is Right
‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney
HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
Need a specific report? 1000+ reports available
Buy Reports